After laying off most of its staff and partnering away its phase 3 cancer asset earlier this year, precision oncology outfit Repare Therapeutics has agreed to be acquired by nonprofit biotech ...

XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ: RPTX). Repare shareholders will receive a cash ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After cutting 75% of its staff ...

Repare Therapeutics said it reached an agreement to be acquired by XenoTherapeutics, in a deal which will see shareholders receive cash and contingent value rights. Under the terms of the deal, Repare ...

- $112.6 million in cash and cash equivalents and marketable securities as of September 30, 2025, as compared to $109.5 million at June 30, 2025 - Repare Therapeutics Inc. (“Repare” or the “Company”) ...

Use commas for lists, dialogue and complex sentences. The hungry comma chameleon is looking for tasty commas to eat. This literary lunching lizard needs your help to find the hidden commas in each ...

Seven months after pressing pause on its plans for its PKMYT1 inhibitor, Repare Therapeutics has found a partner to take the cancer drug forward. Back in January, Repare abandoned phase 3 plans to ...

Following this transaction, Repare will focus on advancing its two ongoing Phase 1 clinical trials. The POLAR trial evaluating RP-3467, a polymerase theta inhibitor, is expected to deliver topline ...

We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Rebecca Firkser My ...